State Street Corp Protagonist Therapeutics, Inc Transaction History

State Street Corp

$2.8 Trillion
Q3 2025

A detailed history of State Street Corp transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, State Street Corp holds 3,165,795 shares of PTGX stock, worth $268 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

3,165,795

Previous 3,207,543 1.3%

Holding current value

$268 Million

Previous $177 Million 18.63%

% of portfolio

0.01%

Previous 0.01%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$49.7 - $67.42 $2.07 Million - $2.81 Million	-41,748 Reduced 1.3%	3,165,795 $210 Million
Q2 2025 Aug 14, 2025	BUY	$40.89 - $56.37 $20.5 Million - $28.2 Million	500,924 Added 18.51%	3,207,543 $177 Million
Q1 2025 May 15, 2025	SELL	$35.09 - $59.76 $21.9 Million - $37.3 Million	-624,442 Reduced 18.75%	2,706,619 $131 Million
Q4 2024 Feb 14, 2025	BUY	$38.51 - $48.43 $5.68 Million - $7.14 Million	147,519 Added 4.63%	3,331,061 $129 Million
Q3 2024 Nov 14, 2024	BUY	$33.72 - $47.33 $37.1 Million - $52.1 Million	1,101,218 Added 52.88%	3,183,542 $143 Million
Q2 2024 Aug 14, 2024	SELL	$24.66 - $34.8 $29.3 Million - $41.4 Million	-1,190,161 Reduced 36.37%	2,082,324 $72.2 Million
Q1 2024 May 15, 2024	BUY	$21.79 - $32.15 $11.8 Million - $17.4 Million	542,556 Added 19.87%	3,272,485 $94.7 Million
Q4 2023 Feb 14, 2024	SELL	$14.05 - $23.44 $17 Million - $28.4 Million	-1,212,209 Reduced 30.75%	2,729,929 $62.6 Million
Q3 2023 Nov 14, 2023	BUY	$16.68 - $23.66 $6.51 Million - $9.23 Million	390,152 Added 10.98%	3,942,138 $65.8 Million
Q2 2023 Aug 14, 2023	BUY	$18.02 - $29.36 $20.5 Million - $33.4 Million	1,138,285 Added 47.16%	3,551,986 $98.1 Million
Q1 2023 May 15, 2023	SELL	$10.78 - $25.38 $14.9 Million - $35 Million	-1,379,225 Reduced 36.36%	2,413,701 $55.5 Million
Q4 2022 Feb 14, 2023	SELL	$7.36 - $11.17 $6.5 Million - $9.87 Million	-883,756 Reduced 18.9%	3,792,926 $41.4 Million
Q3 2022 Nov 15, 2022	SELL	$7.86 - $11.71 $16.5 Million - $24.6 Million	-2,099,587 Reduced 30.98%	4,676,682 $39.4 Million
Q2 2022 Aug 15, 2022	BUY	$7.06 - $25.52 $24.8 Million - $89.8 Million	3,519,461 Added 108.06%	6,776,269 $53.6 Million
Q1 2022 May 16, 2022	BUY	$23.34 - $36.08 $16 Million - $24.7 Million	685,238 Added 26.65%	3,256,808 $77.1 Million
Q4 2021 Feb 14, 2022	BUY	$17.63 - $37.1 $9.83 Million - $20.7 Million	557,591 Added 27.69%	2,571,570 $87.9 Million
Q3 2021 Nov 15, 2021	BUY	$12.95 - $49.69 $7.24 Million - $27.8 Million	559,359 Added 38.45%	2,013,979 $35.7 Million
Q2 2021 Aug 16, 2021	SELL	$25.57 - $44.88 $6.6 Million - $11.6 Million	-258,063 Reduced 15.07%	1,454,620 $65.3 Million
Q1 2021 May 17, 2021	BUY	$19.02 - $31.15 $4.34 Million - $7.11 Million	228,367 Added 15.39%	1,712,683 $44.4 Million
Q4 2020 Feb 16, 2021	BUY	$18.49 - $25.13 $6.1 Million - $8.29 Million	329,763 Added 28.56%	1,484,316 $29.9 Million
Q3 2020 Nov 10, 2020	BUY	$15.19 - $22.4 $11.7 Million - $17.3 Million	771,659 Added 201.53%	1,154,553 $22.6 Million
Q2 2020 Aug 14, 2020	BUY	$6.19 - $18.84 $402,981 - $1.23 Million	65,102 Added 20.49%	382,894 $6.76 Million
Q1 2020 May 11, 2020	BUY	$5.4 - $9.22 $1.72 Million - $2.93 Million	317,792 New	317,792 $2.24 Million

Others Institutions Holding PTGX

# of Institutions

299

Shares Held

68.6M

Call Options Held

125K

Put Options Held

53.1K

View Full List

About Protagonist Therapeutics, Inc

Ticker PTGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,084,100
Market Cap $4.15B
Description
Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...

More about PTGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Protagonist Therapeutics, Inc Transaction History